Ortivus

Delisting Announcement • Dec 16, 2024

Ortivus will change its listing to Nasdaq First North Growth Market on December 19, 2024

Ortivus AB (publ) ("Ortivus" or the "Company") has applied for and today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on the Nasdaq First North Growth Market will be December 19, 2024.

On October 25, 2024, Ortivus announced that the Company's board had decided to initiate a process for changing the list for the Company's shares from Nasdaq Stockholm to Nasdaq First North Growth Market. Ortivus has applied for the delisting of the Company's shares from Nasdaq Stockholm and Nasdaq Stockholm has approved Ortivus' application for delisting. Furthermore, the Company's application for admission to trading on the Nasdaq First North Growth Market has been approved. The last day for trading of the Company's shares on Nasdaq Stockholm will be December 18, 2024, and the first day for trading on Nasdaq First North Growth Market will be December 19, 2024.

The shareholders in Ortivus will not have to take any measures in connection with the list change.

Ortivus has a long history of being in a public environment and thus transparently communicating with market players, which the company will continue to do. As a result of the list change, there is no longer a requirement for Ortivus to apply the Swedish Code of Corporate Governance ("the Code"), but Ortivus will follow the Code in selected parts.

The company will also publish quarterly reports according to IFRS with application of IAS 34. The Board of Directors assesses that a listing of the Company's shares on the Nasdaq First North Growth Market will entail lower costs, among other things, for the stock exchange itself and auditing.

Nasdaq First North Growth Market

Nasdaq First North Growth Market is a registered growth market for small and medium-sized companies in accordance with Directive 2014/65/EU on markets in financial instruments, as implemented in the national legislation of Denmark, Finland and Sweden, and is operated by an exchange within Nasdaq- the group. Issuers on the Nasdaq First North Growth Market are not subject to the same rules as issuers on the regulated market, as defined in EU legislation and implemented in national legislation. They are instead subject to less extensive rules adapted to smaller growth companies. The risks attributable to an investment in an issuer on the Nasdaq First North Growth Market may therefore be higher than an investment in an issuer on the regulated market. Nasdaq Stockholm AB approves the application for admission trading. All issuers whose shares are admitted to trading on the Nasdaq First North Growth Market have a Certified Adviser who monitors compliance with the rules. FNCA Sweden AB is the Company's Certified Adviser. FNCA Sweden AB does not own any shares in the Company.

Contacts

For further information, please contact

Gustaf Nordenhök, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in realtime, MobiMed ePR, - an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, - a tool for navigation and case management, and MobiMed Life - a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

Attachments

Ortivus will change its listing to Nasdaq First North Growth Market on December 19, 2024